兴齐眼药近视防控产品矩阵进一步丰富 又有两款药品获准注册

Core Viewpoint - The approval of two new specifications of atropine sulfate eye drops by the National Medical Products Administration represents a significant expansion of the company's product matrix for myopia prevention, which is expected to drive further growth in its performance [1][2]. Group 1: Product Approval and Specifications - The company received approval for two new specifications of atropine sulfate eye drops: 0.02% (0.4ml: 0.08mg) and 0.04% (0.4ml: 0.16mg) [1]. - The previously approved 0.01% (0.4ml: 0.04mg) specification is the first eye drop product approved in China for myopia-related indications [2]. - The new products are based on existing formulations and are expected to enhance the company's offerings in the myopia prevention market [2]. Group 2: Financial Performance - The company has experienced rapid growth in recent years, with a 32.42% increase in revenue and a 40.84% increase in net profit attributable to shareholders in 2024 compared to 2023 [2]. - In the first three quarters of the current year, the company's revenue grew by 32.27%, while net profit surged by 105.98% [2]. Group 3: Market Context and Future Outlook - The increasing prevalence of myopia, particularly among children and adolescents, presents a significant public health challenge and a large market opportunity for myopia prevention products [3]. - The introduction of the new products is expected to optimize the company's product matrix for myopia prevention, providing more options for patients and potentially enhancing the company's growth [3]. - The company is actively exploring different mechanisms for myopia prevention based on foundational research, indicating a commitment to expanding its product offerings in this area [3].